Nektar Therapeutics (NASDAQ:NKTR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Nektar Therapeutics (NASDAQ:NKTRGet Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03, Zacks reports. Nektar Therapeutics had a negative return on equity of 101.41% and a negative net margin of 195.02%. The firm had revenue of $21.64 million during the quarter, compared to the consensus estimate of $14.91 million. During the same period last year, the company earned ($0.25) EPS.

Nektar Therapeutics Trading Up 10.0 %

NKTR traded up $0.16 on Friday, hitting $1.76. 2,360,209 shares of the company were exchanged, compared to its average volume of 1,997,249. The firm has a 50-day moving average price of $1.20 and a two-hundred day moving average price of $0.78. Nektar Therapeutics has a twelve month low of $0.41 and a twelve month high of $1.87.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NKTR shares. assumed coverage on shares of Nektar Therapeutics in a research note on Friday, January 26th. They issued a “hold” rating on the stock. Jefferies Financial Group raised their price target on Nektar Therapeutics from $0.50 to $1.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. Finally, William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research note on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. According to data from, the stock has an average rating of “Hold” and an average target price of $3.50.

Read Our Latest Stock Analysis on NKTR

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

Read More

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with's FREE daily email newsletter.